Küçükhüseyin Özlem, Kurnaz Özlem, Akadam-Teker A Basak, Narter Fehmi, Yılmaz-Aydoğan Hülya, İsbir Turgay
Department of Molecular Medicine, Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey.
Asian Pac J Cancer Prev. 2011;12(9):2275-8.
Prostate cancer is the most common malignancy and the second leading cause of cancer related deaths among men in many countries. Serum levels of prostate-spesific antigen (PSA) have attracted attention for prediction purposes. The methylenetetrahydrofolate reductase (MTHFR) gene play a critical role in cancer development, but its potential impact on prostate cancer has not been well studied. The C677T variant lies in exon 4 at the folate binding site of the MTHFR gene and results in substitution of an alanine by a valine residue. The present study was carried out 55 cases with prostate cancer and 50 healthy men. Polymerase chain reaction (PCR), restriction fragment length polymorphism (RFLP), and agarose gel electrophoresis techniques were employed to determine MTHFR C677T mutation. The frequencies of the CT genotype (p= 0.025) and T allele (p= 0.023) was found to be higher in control subjects when compared with patients group. No statistical difference was found between the alleles of MTHFR and PSA levels after (PSA-BT)/ before (PSA-AT) antiandrogen treatment or tumor stages. We suggest that the heterozygote CT genotype and the 677T allele of the MTHFR polymorphism might be associated with an decreased prostate cancer risk.
前列腺癌是许多国家男性中最常见的恶性肿瘤，也是癌症相关死亡的第二大主要原因。血清前列腺特异性抗原（PSA）水平已引起人们对预测目的的关注。亚甲基四氢叶酸还原酶（MTHFR）基因在癌症发展中起关键作用，但其对前列腺癌的潜在影响尚未得到充分研究。C677T变异位于MTHFR基因叶酸结合位点的第4外显子，导致丙氨酸被缬氨酸残基取代。本研究对55例前列腺癌患者和50名健康男性进行。采用聚合酶链反应（PCR）、限制性片段长度多态性（RFLP）和琼脂糖凝胶电泳技术来确定MTHFR C677T突变。与患者组相比，对照组中CT基因型（p = 0.025）和T等位基因（p = 0.023）的频率更高。在抗雄激素治疗后（PSA - BT）/治疗前（PSA - AT）或肿瘤分期后，MTHFR等位基因与PSA水平之间未发现统计学差异。我们认为，MTHFR多态性的杂合子CT基因型和677T等位基因可能与前列腺癌风险降低有关。
